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Background: Multiple myeloma (MM) is the most
common plasma cell disorder with an incidence of 4-5
new cases per 100,000 individuals per year. High dose
chemotherapy with melphalan followed by autologous
stem cell transplantation (SCT) is considered the standard
of care. Melphalan 200 mg/m2 is considered the gold
standard conditioning regimen prior to autologous SCT.
The Intergroupe Francophone du Myélome randomized
trial conﬁrmed that patients receiving melphalan 200 mg/
m2 displayed a better median overall survival as
compared to patients treated with melphalan 140 mg/m2
in combination with total body irradiation (65 vs. 45%
survival at 45 months). Melphalan 200 mg/m2 has been
administered over 1-day or given over two consecutive
days (100 mg/m2 per day). Limited data exist on optimal
schedule of dosing and to date, direct comparative
efﬁcacy analyses have not been conducted between 1-day
versus 2-day melphalan administration. As of March
2012, the Blood and Marrow Transplantation Service at
Mofﬁtt Cancer Center changed the melphalan condi-
tioning regimens from 2-day dosing (100 mg/m2 per day)
to 1-day dosing (200 mg/m2per day). An evaluation
will be performed in order to determine if there is
a difference in the effects on patients’ transplant
complications, engraftment, and response rates between
the two groups.
The dose-limiting toxicity of melphalan is oral muco-
sitis which is associated with prolonged hospitalization.
Grazziutti, et al found that higher melphalan doses and
renal dysfunction (both reﬂecting increased melphalan
exposure) were key pre-transplant risk factors for severe
oral mucositis following autologous SCT; all doses were
administered over 1-day. Parallel to this study, Palumbo, et
al found a greater incidence of non-hematologic toxicities
in patients who received higher doses of melphalan
although this study evaluated melphalan 200 mg/m2
versus 100 mg/m2; all doses were administered over 1-day.
Along with toxicity proﬁle, it is unknown whether
administering melphalan over 1-day versus 2-days will
affect response rates post-transplantation and progres-
sion-free survival of patients. We propose a retrospective
comparison between patients who have received 1-day
melphalan versus 2-day melphalan to evaluate these
outcomes.
Study Design: A retrospective chart review of all patients
with MM receiving high dose melphalan for autologous SCT
from January 2010-October 2012 will be conducted.
Patient Population: Inclusion criteria:1 All patients with primary diagnosis of MM undergoing
autologous SCT
2 Conditioning regimen consisting of melphalan 200
mg/m2
3 18 years of age and older
Exclusion criteria:
1 Patients who received reduced dose melphalan, 140
mg/m2, as conditioning regimen
2 For patients who received tandem autologous SCT, only
the ﬁrst SCT will be evaluated
Results: Preliminary results to be presented.551
Therapeutic Drug Monitoring (TDM) of Cyclosporine
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Introduction: The controversy surrounding cyclosporine
TDM is still ongoing. In HSCT practice, the C0 method (or
trough) is the one most commonly employed. At the CHU
Sainte-Justine, the AUC method has been used for cyclo-
sporine TDM in HSCT patients since October 2009. The aim of
this study was to evaluate the correlation between cyclo-
sporine levels (AUC or C0) with nephrotoxicity and GVHD in
a pediatric population.
Methods: Forty-seven patients treated by IV cyclosporine for
a ﬁrst HSCT and having at least two AUCs were included in
this retrospective study. Our protocol stipulates that
a complete AUC (9 samples) must be done seven days after
the beginning of the intravenous cyclosporine and partial
AUCs (3 samples) once a week. All AUCs also include a C0.
GVHDwas deﬁned as acute or chronic GVHD of any grade for
the duration of the post-transplant follow-up. The patients
were evaluated for the occurrence of nephrotoxicity
according to the AKIN criteria.
Results: Median age of patients was 10.4 years (0.19-20.9).
A total of 176 AUC samples were included (55 complete
and 121 partial). Fourteen patients (30%) were diagnosed
with GVHD and 23 (49%) with nephrotoxicity (AKIN stage
1, 2 or 3 at least one day for the duration of the IV
cyclosporine).Conclusion: No correlation was found between the cyclo-
sporine levels (AUC or C0) and the occurrence of GVHD or
nephrotoxicity. Many confounding factors can inﬂuence
theses issues and the small number of patients limits the
extent of these ﬁndings.
